AI assistant
Sending…
AIM ImmunoTech Inc. — Director's Dealing 2017
Feb 21, 2017
35334_dirs_2017-02-21_177a755f-6447-4413-9bb7-fdf0816dd528.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2017-02-16
Reporting Person: Pascale Adam (CFO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-02-16 | Common Stock | P | 6981 | $0.46 | Acquired | 11516 | Direct |